Schroder Investment Management Group Raises Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Schroder Investment Management Group lifted its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 145.1% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,229,786 shares of the company's stock after purchasing an additional 1,320,076 shares during the period. Schroder Investment Management Group owned approximately 0.20% of Teva Pharmaceutical Industries worth $49,769,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in TEVA. Janus Henderson Group PLC raised its position in Teva Pharmaceutical Industries by 7,945.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company's stock valued at $86,350,000 after purchasing an additional 4,732,374 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd increased its stake in shares of Teva Pharmaceutical Industries by 12.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after buying an additional 4,418,961 shares during the period. Todd Asset Management LLC acquired a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $58,243,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Teva Pharmaceutical Industries by 237.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,377,517 shares of the company's stock worth $60,863,000 after acquiring an additional 2,376,668 shares during the last quarter. Finally, State Street Corp increased its position in shares of Teva Pharmaceutical Industries by 10.0% in the 3rd quarter. State Street Corp now owns 19,500,683 shares of the company's stock valued at $351,402,000 after purchasing an additional 1,778,268 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

TEVA has been the subject of a number of research analyst reports. Piper Sandler upped their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, January 17th. UBS Group reduced their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. Bank of America cut their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Barclays dropped their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. Finally, StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Friday. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $23.43.

Teva Pharmaceutical Industries Stock Performance

TEVA traded down $1.25 during trading on Friday, reaching $13.61. The company's stock had a trading volume of 11,979,372 shares, compared to its average volume of 9,713,685. The company has a market capitalization of $15.43 billion, a price-to-earnings ratio of -9.37, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. The company's fifty day moving average price is $16.67 and its 200-day moving average price is $18.04. Teva Pharmaceutical Industries Limited has a 52-week low of $12.51 and a 52-week high of $22.80. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, equities analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.